Heterogeneity of osteosarcoma cell lines led to variable responses in reprogramming

International Journal of Medical Sciences

Volumn 11, Issue 11, 2014, Pages 1154-1160

  Choong, Pei Feng ^a,b   Teh, Hui Xin ^b   Teoh, Hoon Koon ^a   Ong, Han Kiat ^b   Choo, Kong Bung ^b   Sugii, Shigeki ^c,d   Cheong, Soon Keng ^a,b   Kamarul, Tunku ^e  

^a MAKNA HUKM Cancer Institute   (Malaysia)

^b UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

^c AGENCY FOR SCIENCE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Cancer cells; Embryonic stem cells; Heterogeneity; Osteosarcoma; Pluripotency; Reprogramming

Indexed keywords

ALKALINE PHOSPHATASE; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2; MEMBRANE ANTIGEN; POU5F1 PROTEIN, HUMAN; PROTEOGLYCAN; STAGE SPECIFIC EMBRYO ANTIGEN; STAGE-SPECIFIC EMBRYONIC ANTIGEN-4; TRA-1-60 ANTIGEN, HUMAN; TRA-1-81 ANTIGEN, HUMAN;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL STRAIN; CELL STRUCTURE; CELL SUSPENSION; EMBRYO; EMBRYOID BODY; EMBRYONIC STEM CELL; G 292 CELL LINE; HUMAN; HUMAN CELL; MG 63 CELL LINE; NONHUMAN; NUCLEAR REPROGRAMMING; OSTEOCYTE; OSTEOSARCOMA CELL LINE; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SAOS 2 CELL LINE; SARCOMA; U 2 OS CELL LINE; CYTOLOGY; GENETICS; METABOLISM; OSTEOSARCOMA; PHYSIOLOGY; TUMOR CELL LINE;

ANTIGENS, SURFACE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; EMBRYONIC STEM CELLS; HUMANS; OCTAMER TRANSCRIPTION FACTOR-3; OSTEOCYTES; OSTEOSARCOMA; PROTEOGLYCANS; STAGE-SPECIFIC EMBRYONIC ANTIGENS;

EID: 84906748256     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8281     Document Type: Article

References (29)

1. Weinstein IB, Case K. The history of Cancer Research: introducing an AACR Centennial series. Cancer Res. 2008; 68: 6861-62.
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76.
3. Puri MC, Nagy A. Concise review: Embryonic stem cells versus induced pluripotent stem cells: the game is on. Stem Cells. 2012; 30: 10-4.
4. Amabile G, Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends in Molecular Medicine. 2009; 15: 59-68.
5. Lu SJ, Lee RJ, Napoli C, Oh S, Kimbrel EA, Feng Q. The promise and therapeutic potential of human ES and iPS cells. Stem Cells Int. 2011; 2011: 959275.
6. Tafani M. Reprogramming cancer stem cells. J Cancer Sc Ther. 2012; 4: xxv-xxvi.
7. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene. 2013; 32: 2249-60.
8. Spike BT, Wahl GM. p53, stem cells, and reprogramming: Tumor suppression beyond guarding the genome. Genes & cancer. 2011; 2: 404-19.
9. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol. 2006; 7: 14.
10. Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res. 2008; 68: 4229-38.
11. Briquet A, Dubois S, Bekaert S, Dolhet M, Beguin Y, Gothot A. Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Hematologica. 2010; 95: 47-56.
12. Yuan J, Ossendorf C, Szatkowski JP, Bronk JT, Yaszemski M, Bolander ME, et al. Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases. Cancer Invest. 2009; 27: 435-42.
13. Gibbs CP, Levings PP, Ghivizzani SC. Evidence for the osteosarcoma stem cell. Curr Orthop Pract. 2011; 22: 322-6.
14. Sugii S, Kida Y, Berggren WT, Evans RM. Feeder-dependent and feeder-independent iPS cell derivation from human and mouse adipose stem cells. Nature Protocols. 2011; 6: 346-58.
15. Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, Camargo FD, et al. Generation of iPSCs from cultured human malignant cells. Blood. 2010; 115: 4039-42.
16. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. PNAS. 2010; 107: 40-5.
17. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DTS, Chen DT, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008; 14: 2115-24.
18. Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009; 122: 3502-10.
19. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocrine-related Cancer. 2000; 7: 143-64.
20. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151: 56-67.
21. Lin ZS, Chu HC, Yen YC, Lewis BC, Chen YW. Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PloS One 2012; 7: e43593.
22. Le Magnen C, Bubendorf L, Ruiz C, Zlobec I, Bachmann A, Heberer M, et al. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells. Euro J Cancer. 2013; 49: 955-63.
23. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008; 451: 141-6.
24. Hellwinkel OJC, Müller J, Pollmann A, Kabisch H. Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes. J Gene Med. 2005; 7: 407-19.
25. Pautke C, Schieker M, Tischer T, Kolk A, Neth P, Mutschler W, et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res. 2004; 24: 3743-8.
26. Benayahu D, Shur I, Marom R, Meller I, Issakov J. Cellular and molecular properties associated with osteosarcoma. Cells. 2002; 114: 108-14.
27. Fromigué O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem. 2008; 283: 30549-56.
28. Lucero CM, Vega OA, Osorio MM, Tapia JC, Antonelli M, Stein GS, et al. The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol. 2013; 228: 714-23.
29. Xu Y, Wei X, Wang M, Zhang R, Fu Y, Xing M, et al. Proliferation rate of somatic cells affects reprogramming efficiency. J Biol Chem. 2013; 288: 9767-78.